dapagliflozin/olmesartan medoxomil (ATB-101) / Autotelic, Jeil - LARVOL DELTA

Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes (clinicaltrials.gov) - P3 | N=255 | Completed | Sponsor: Autotelicbio | Trial primary completion date: Jan 2024 ➔ Aug 2025 | Recruiting ➔ Completed | Trial completion date: Jun 2024 ➔ Feb 2026

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study to Compare the Pharmacokinetics and Safety of the ATB-U101 and ATB-U1011+ATB-U1012 and ATB-1011+ATB-1012 in Healthy Caucasian Participants (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Autotelicbio

New P1 trial • Cardiovascular • Hypertension

Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes (clinicaltrials.gov) - P3 | N=248 | Recruiting | Sponsor: Autotelicbio | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes (clinicaltrials.gov) - P3 | N=248 | Not yet recruiting | Sponsor: Autotelicbio

New P3 trial • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus